Researchers at the University of Michigan are seeking people to take part in a study evaluating an experimental medicine for type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease.
According to the university's clinical trial website, participants will take Amlexanox for twelve weeks. There will also be a follow-up evaluation in Ann Arbor.
To be considered for the study, researchers say you must meet a number of conditions, including having type 2 diabetes or being obese, having advanced liver disease and being between the ages of 18 and 60.
For more information, visit umclinicalstudies.org/HUM00065177 or call (734) 615-0539.